Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04412772 · ClinicalTrials.gov registry record · Phase 3
Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS
A Phase 3 study, sponsored by Queen's Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT04412772 is a Phase 3 study that was terminated before completion, run by Queen's Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT04412772, a Phase 3 study, was terminated before completion, sponsored by Queen's Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The overall objective is to evaluate the clinical efficacy and safety of tocilizumab relative to placebo among approximately 300 hospitalized adult patients who have severe COVID-19. The study will be a 2 arm double blinded comparison between tocilizumab 8 mg/kg and matching placebo IV. The dose may be repeated in 8-12 hours if clinical symptoms worsens, (e.g. increase in oxygen requirements). Participants will be followed for 28 days.
Interventions
- DRUG Placebo
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04412772
The ClinicalTrials.gov registry entry for NCT04412772 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Queen's Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04412772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04412772 about?
NCT04412772 is a clinical study titled "Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS". The overall objective is to evaluate the clinical efficacy and safety of tocilizumab relative to placebo among approximately 300 hospitalized adult patients who have severe COVID-19. The study will be a 2 arm double blinded comparison between tocilizumab 8 mg/kg and matching placebo IV. The dose may...
What is the current status of trial NCT04412772?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2020-06-12. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT04412772?
The interventions under investigation include: Placebo (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT04412772?
This trial is sponsored by Queen's Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.